

Seasonal Influenza Vaccines

H. Keipp Talbot, MD, MPH
Chair, Influenza Work Group

Advisory Committee on Immunization Practices
February 25, 2021

Influenza Work Group

ACIP Members

Keipp Talbot (Chair)
Kevin Ault
Hank Bernstein
Camille Kotton

Ex Officio Members

Michael Cooper (NIH)
Cynthia Nolletti (FDA)
Chris Roberts (NIH)
Susan Wollersheim (FDA)

Liaison Representatives and Consultants

Robert Atmar
Ed Belongia
Sarah Coles
Buddy Creech
Sarah Despres
Jeff Duchin
Sandra Fryhofer
Robyn Harrison
Denise Jamieson
Wendy Keitel
Marie-Michèle Léger
Jamie Loehr
Susan Lett

Mark Mulligan
Flor Munoz
Kathy Neuzil
William Schaffner
Rob Schechter
Ken Schmader
Patsy Stinchfield
Tamara Sheffield
Angela Sinilaite
Peter Szilagyi
Chip Walter
Matthew Zahn

Recap of Influenza Session, October 2020

- Results from an efficacy study of Flucelvax Quadrivalent (cell culture-based inactivated influenza vaccine) among children ≥ 2 through < 18 years of age
 - Currently approved for ages 4 years and older
- Estimates of influenza burden and burden averted by vaccination in the United States during the 2019-20 season
- End-of-season estimates of 2019–20 seasonal influenza vaccine effectiveness against medically attended influenza from three U.S. Networks
 - U.S. Influenza Vaccine Effectiveness (U.S. Flu VE) Network
 - Hospitalized Adults Influenza Vaccine Effectiveness Network (HAIVEN)
 - New Vaccine Surveillance Network (NVSN)

Current/Ongoing WG Discussion Topics

- Proposed updates to the ACIP influenza statement for the 2021-22 season
 - Ongoing; to be presented in June, 2021
- Review of influenza vaccines for older adults

Session Overview

- **Influenza surveillance, vaccine coverage and WG discussion update**
 - Lisa Grohskopf, CDC/NCIRD/Influenza Division